Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1802]

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective

Dr Ricky Frazer and Dr Sree Subramanian

Managing gastrotoxicities for RCC treatment – Gastroenterologist's perspective ( Dr Ricky Frazer and Dr Sree Subramanian )

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid...

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA

WRN inhibitor shows promise in patients with MSI and/or dMMR advanced solid tumours ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers

Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA

Olaparib plus pembrolizumab shows promising results in BRCA mutated cancers ( Dr Timothy A. Yap - UT MD Anderson Cancer Center, Houston, USA )

ELCC 2025: Latest in EGFR positive NSCLC

Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna...

ELCC 2025: Latest in EGFR positive NSCLC ( Dr Antonio Passaro, Prof Nicolas Girard, Prof Raffaele Califano and Dr Anna Minchom )

Consolidation durvalumab after cCRT shows decreased disease progression in LS...

Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands

Consolidation durvalumab after cCRT shows decreased disease progression in LS-SCLC ( Prof Suresh Senan - University Medical Centers, Amsterdam, The Netherlands )

Urine test could reduce post-op scans for kidney cancer by half

Dr Saeed Dabestani - Lund university, Lund, Sweden

Urine test could reduce post-op scans for kidney cancer by half ( Dr Saeed Dabestani - Lund university, Lund, Sweden )

Bone-protective agents given with enzalutamide with or without radium-223 show...

Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada

Bone-protective agents given with enzalutamide with or without radium-223 show greater survival benefits in mCRPC ( Prof Fred Saad - University of Montreal Hospital Center, Montreal, Canada )

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant...

Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston...

Isatuximab with VRd can benefit newly diagnosed multiple myeloma transplant ineligible patients ( Prof Robert Orlowski - University of Texas MD Anderson Cancer Center, Houston, USA )

Talazoparib and enzalutamide combination therapy shows significant benefit in...

Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA

Talazoparib and enzalutamide combination therapy shows significant benefit in treating mCRPC ( Prof Neeraj Agarwal - University of Utah, Salt Lake City, USA )

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide...

Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center...

Mevrometostat and enzalutamide show improved outcomes compared to enzalutamide alone in mCRPC ( Dr Michael Schweizer - University of Washington Fred Hutch Cancer Center, Seattle, Washington )

Time to metastasis after prostatectomy should not be used as a prognostic...

Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA

Time to metastasis after prostatectomy should not be used as a prognostic factor for metachronous mHSPC ( Dr Nicolas Sayegh - UT Southwestern Medical Center, Dallas, USA )

SIOG 2024: Updates in medical oncology

Dr Capucine Baldini - Gustave Roussy, Villejuif, France

SIOG 2024: Updates in medical oncology ( Dr Capucine Baldini - Gustave Roussy, Villejuif, France )

More from ecancer